Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination

Autoimmunity Reviews

Volumn 15, Issue 4, 2016, Pages 307-324

  Ramanathan, Sudarshini ^a,b   Dale, Russell C ^a   Brilot, Fabienne ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Acute disseminated encephalomyelitis; Bilateral optic neuritis; Longitudinally extensive transverse myelitis; Multiple sclerosis; Myelin oligodendrocyte glycoprotein antibodies; Neuromyelitis optica spectrum disorder

Indexed keywords

ANTIBODY; AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; BIOLOGICAL MARKER; EPITOPE; IMMUNOGLOBULIN G; INTERFERON; MYCOPHENOLIC ACID; MYELIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; NATALIZUMAB; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANTIBODY DETECTION; ANTIGEN BINDING; AUTOIMMUNITY; BINDING SITE; DEMYELINATION; DISABILITY; DISEASE ASSOCIATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; MULTIPLE SCLEROSIS; MURINE MODEL; MYELOOPTIC NEUROPATHY; NONHUMAN; PATHOGENICITY; PHENOTYPE; PROGNOSIS; PROTEIN CONFORMATION; REVIEW; ANIMAL; BLOOD; IMMUNOLOGY;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; BIOMARKERS; HUMANS; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PHENOTYPE;

EID: 84959095122     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.12.004     Document Type: Review

References (140)

1. Brunner C., Lassmann H., Waehneldt T.V., Matthieu J.M., Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats. J Neurochem 1989, 52:296-304.
2. Schluesener H.J., Sobel R.A., Linington C., Weiner H.L. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987, 139:4016-4021.
3. Pham-Dinh D., Mattei M.G., Nussbaum J.L., Roussel G., Pontarotti P., Roeckel N., et al. Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. Proc Natl Acad Sci U S A 1993, 90:7990-7994.
4. Gardinier M.V., Amiguet P., Linington C., Matthieu J.M. Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J Neurosci Res 1992, 33:177-187.
5. Pham-Dinh D., Allinquant B., Ruberg M., Della Gaspera B., Nussbaum J.L., Dautigny A. Characterization and expression of the cDNA coding for the human myelin/oligodendrocyte glycoprotein. J Neurochem 1994, 63:2353-2356.
6. Linington C., Bradl M., Lassmann H., Brunner C., Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988, 130:443-454.
7. Freedman M.S., Thompson E.J., Deisenhammer F., Giovannoni G., Grimsley G., Keir G., et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005, 62:865-870.
8. Esiri M.M. Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet 1977, 2:478.
9. Esiri M.M. Multiple sclerosis: a quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system. Neuropathol Appl Neurobiol 1980, 6:9-21.
10. Prineas J.W., Graham J.S. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 1981, 10:149-158.
11. Storch M.K., Piddlesden S., Haltia M., Iivanainen M., Morgan P., Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998, 43:465-471.
12. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999, 5:170-175.
13. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
14. Linnington C., Webb M., Woodhams P.L. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol 1984, 6:387-396.
15. Linington C., Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J Neuroimmunol 1987, 17:61-69.
16. Ichikawa M., Johns T.G., Liu J., Bernard C.C. Analysis of the fine B cell specificity during the chronic/relapsing course of a multiple sclerosis-like disease in Lewis rats injected with the encephalitogenic myelin oligodendrocyte glycoprotein peptide 35-55. J Immunol 1996, 157:919-926.
17. Adelmann M., Wood J., Benzel I., Fiori P., Lassmann H., Matthieu J.M., et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 1995, 63:17-27.
18. Mathey E.K., Derfuss T., Storch M.K., Williams K.R., Hales K., Woolley D.R., et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007, 204:2363-2372.
19. Johns T.G., Kerlero de Rosbo N., Menon K.K., Abo S., Gonzales M.F., Bernard C.C. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol 1995, 154:5536-5541.
20. Ichikawa M., Johns T.G., Adelmann M., Bernard C.C. Antibody response in lewis rats injected with myelin oligodendrocyte glycoprotein derived peptides. Int Immunol 1996, 8:1667-1674.
21. Breithaupt C., Schafer B., Pellkofer H., Huber R., Linington C., Jacob U. Demyelinating myelin oligodendrocyte glycoprotein-specific autoantibody response is focused on one dominant conformational epitope region in rodents. J Immunol 2008, 181:1255-1263.
22. Haase C.G., Guggenmos J., Brehm U., Andersson M., Olsson T., Reindl M., et al. The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J Neuroimmunol 2001, 114:220-225.
23. von Budingen H.C., Hauser S.L., Fuhrmann A., Nabavi C.B., Lee J.I., Genain C.P. Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination. Proc Natl Acad Sci U S A 2002, 99:8207-8212.
24. Breithaupt C., Schubart A., Zander H., Skerra A., Huber R., Linington C., et al. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci U S A 2003, 100:9446-9451.
25. von Budingen H.C., Hauser S.L., Ouallet J.C., Tanuma N., Menge T., Genain C.P. Frontline: epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur J Immunol 2004, 34:2072-2083.
26. Brehm U., Piddlesden S.J., Gardinier M.V., Linington C. Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J Neuroimmunol 1999, 97:9-15.
27. de Graaf K.L., Albert M., Weissert R. Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity. J Biol Chem 2012, 287:17206-17213.
28. Ohtani S., Kohyama K., Matsumoto Y. Autoantibodies recognizing native MOG are closely associated with active demyelination but not with neuroinflammation in chronic EAE. Neuropathology 2011, 31:101-111.
29. Mathey E., Breithaupt C., Schubart A.S., Linington C. Commentary: sorting the wheat from the chaff: identifying demyelinating components of the myelin oligodendrocyte glycoprotein (MOG)-specific autoantibody repertoire. Eur J Immunol 2004, 34:2065-2071.
30. Marta C.B., Oliver A.R., Sweet R.A., Pfeiffer S.E., Ruddle N.H. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 2005, 102:13992-13997.
31. Bansal P., Khan T., Bussmeyer U., Challa D.K., Swiercz R., Velmurugan R., et al. The encephalitogenic, human myelin oligodendrocyte glycoprotein-induced antibody repertoire is directed toward multiple epitopes in C57BL/6-immunized mice. J Immunol 2013, 191:1091-1101.
32. Menge T., Lalive P.H., von Budingen H.C., Genain C.P. Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis. J Neuroinflammation 2011, 8:161.
33. Reindl M., Linington C., Brehm U., Egg R., Dilitz E., Deisenhammer F., et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999, 122(Pt 11):2047-2056.
34. Karni A., Bakimer-Kleiner R., Abramsky O., Ben-Nun A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol 1999, 56:311-315.
35. Markovic M., Trajkovic V., Drulovic J., Mesaros S., Stojsavljevic N., Dujmovic I., et al. Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 2003, 211:67-73.
36. Gaertner S., de Graaf K.L., Greve B., Weissert R. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 2004, 63:2381-2383.
37. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999, 122(Pt 11):2089-2100.
38. Egg R., Reindl M., Deisenhammer F., Linington C., Berger T. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 2001, 7:285-289.
39. Kuhle J., Lindberg R.L., Regeniter A., Mehling M., Hoffmann F., Reindl M., et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 2007, 254:160-168.
40. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003, 349:139-145.
41. Rauer S., Euler B., Reindl M., Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006, 77:739-742.
42. Tomassini V., De Giglio L., Reindl M., Russo P., Pestalozza I., Pantano P., et al. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 2007, 13:1086-1094.
43. Greeve I., Sellner J., Lauterburg T., Walker U., Rosler K.M., Mattle H.P. Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort. Acta Neurol Scand 2007, 116:207-210.
44. O'Connor K.C., Appel H., Bregoli L., Call M.E., Catz I., Chan J.A., et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005, 175:1974-1982.
45. Pittock S.J., Reindl M., Achenbach S., Berger T., Bruck W., Konig F., et al. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler 2007, 13:7-16.
46. Lutterotti A., Reindl M., Gassner C., Poustka K., Schanda K., Deisenhammer F., et al. Antibody response to myelin oligodendrocyte glycoprotein and myelin basic protein depend on familial background and are partially associated with human leukocyte antigen alleles in multiplex families and sporadic multiple sclerosis. J Neuroimmunol 2002, 131:201-207.
47. Lampasona V., Franciotta D., Furlan R., Zanaboni S., Fazio R., Bonifacio E., et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 2004, 62:2092-2094.
48. Lim E.T., Berger T., Reindl M., Dalton C.M., Fernando K., Keir G., et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005, 11:492-494.
49. Kuhle J., Pohl C., Mehling M., Edan G., Freedman M.S., Hartung H.P., et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007, 356:371-378.
50. Pelayo R., Tintore M., Montalban X., Rovira A., Espejo C., Reindl M., et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 2007, 356:426-428.
51. Wang H., Munger K.L., Reindl M., O'Reilly E.J., Levin L.I., Berger T., et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 2008, 71:1142-1146.
52. Khalil M., Reindl M., Lutterotti A., Kuenz B., Ehling R., Gneiss C., et al. Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: influence of relapses and immunomodulatory treatments. J Neuroimmunol 2006, 174:147-156.
53. Menge T., von Budingen H.C., Lalive P.H., Genain C.P. Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid-phase ELISA. Eur J Immunol 2007, 37:3229-3239.
54. Reder A.T., Oger J.J. Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Neurology 2004, 62:1922-1923.
55. Sinmaz N., Amatoury M., Merheb V., Ramanathan S., Dale R.C., Brilot F. Autoantibodies in movement and psychiatric disorders: updated concepts in detection methods, pathogenicity, and CNS entry. Ann N Y Acad Sci 2015, 1351:22-38.
56. Waters P., Woodhall M., O'Connor K.C., Reindl M., Lang B., Sato D.K., et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015, 2.
57. Dale R.C., Tantsis E., Merheb V., Kumaran R.-Y.A., Sinmaz N., Pathmanandavel K., et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 2014, 1.
58. Ramanathan S., Reddel S.W., Henderson A., Parratt J.D.E., Barnett M., Gatt P.N., et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2014, 1(4).
59. Ramanathan S., Sato S., Matsushita T., Masaki K., Yamasaki R., Dale R.C., et al. Antibodies to myelin oligodendrocyte glycoprotein are uncommon in Japanese opticospinal multiple sclerosis. Mult Scler 2015, [pii: 1352458515586089 Epub ahead of print].
60. O'Connor K.C., McLaughlin K.A., De Jager P.L., Chitnis T., Bettelli E., Xu C., et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007, 13:211-217.
61. McLaughlin K.A., Chitnis T., Newcombe J., Franz B., Kennedy J., McArdel S., et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009, 183:4067-4076.
62. Brilot F., Dale R.C., Selter R.C., Grummel V., Kalluri S.R., Aslam M., et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009, 66:833-842.
63. Lalive P.H., Hausler M.G., Maurey H., Mikaeloff Y., Tardieu M., Wiendl H., et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011, 17:297-302.
64. Di Pauli F., Mader S., Rostasy K., Schanda K., Bajer-Kornek B., Ehling R., et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011, 138:247-254.
65. Probstel A.K., Dornmair K., Bittner R., Sperl P., Jenne D., Magalhaes S., et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011, 77:580-588.
66. Lalive P.H., Menge T., Delarasse C., Della Gaspera B., Pham-Dinh D., Villoslada P., et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103:2280-2285.
67. Zhou D., Srivastava R., Nessler S., Grummel V., Sommer N., Bruck W., et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103:19057-19062.
68. Mader S., Gredler V., Schanda K., Rostasy K., Dujmovic I., Pfaller K., et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011, 8:184.
69. Chan A., Decard B.F., Franke C., Grummel V., Zhou D., Schottstedt V., et al. Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis. Mult Scler 2010, 16:1189-1192.
70. Fernandez-Carbonell C., Vargas-Lowy D., Musallam A., Healy B., McLaughlin K., Wucherpfennig K.W., et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 2015, [pii: 1352458515587751 Epub ahead of print].
71. Olsson T. White matter disease: roles of anti-MOG antibodies in demyelinating diseases. Nat Rev Neurol 2011, 7:248-249.
72. Baumann M., Sahin K., Lechner C., Hennes E.M., Schanda K., Mader S., et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015, 86:265-272.
73. Ketelslegers I.A., Van Pelt D.E., Bryde S., Neuteboom R.F., Catsman-Berrevoets C.E., Hamann D., et al. Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler 2015, 21:1513-1520.
74. Hacohen Y., Absoud M., Deiva K., Hemingway C., Nytrova P., Woodhall M., et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2015, 2.
75. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
76. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
77. Mandler R.N., Ahmed W., Dencoff J.E. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219-1220.
78. Keegan M., Pineda A.A., McClelland R.L., Darby C.H., Rodriguez M., Weinshenker B.G. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002, 58:143-146.
79. Kitley J., Leite M.I., Nakashima I., Waters P., McNeillis B., Brown R., et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012, 135:1834-1849.
80. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
81. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
82. Bradl M., Misu T., Takahashi T., Watanabe M., Mader S., Reindl M., et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009, 66:630-643.
83. Saini H., Rifkin R., Gorelik M., Huang H., Ferguson Z., Jones M.V., et al. Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis. BMC Neurol 2013, 13:104.
84. Kinoshita M., Nakatsuji Y., Kimura T., Moriya M., Takata K., Okuno T., et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009, 386:623-627.
85. Saadoun S., Waters P., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
86. Wu X., Zhou M., Ding H., Xu S., Wang C., Chan P. Myelin oligodendrocyte glycoprotein induces aquaporin-4 autoantibodies in mouse experimental autoimmune encephalomyelitis. J Neuroimmunol 2013, 261:1-6.
87. Diamond B., Honig G., Mader S., Brimberg L., Volpe B.T. Brain-reactive antibodies and disease. Annu Rev Immunol 2013, 31:345-385.
88. Waters P.J., McKeon A., Leite M.I., Rajasekharan S., Lennon V.A., Villalobos A., et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012, 78:665-671.
89. Marignier R., Bernard-Valnet R., Giraudon P., Collongues N., Papeix C., Zephir H., et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 2013, 80:2194-2200.
90. Jiao Y., Fryer J.P., Lennon V.A., Jenkins S.M., Quek A.M., Smith C.Y., et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013, 81:1197-1204.
91. Ishikawa N., Tajima G., Hyodo S., Takahashi Y., Kobayashi M. Detection of autoantibodies against NMDA-type glutamate receptor in a patient with recurrent optic neuritis and transient cerebral lesions. Neuropediatrics 2007, 38:257-260.
92. Kruer M.C., Koch T.K., Bourdette D.N., Chabas D., Waubant E., Mueller S., et al. NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology 2010, 74:1473-1475.
93. Jarius S., Wandinger K.P., Borowski K., Stoecker W., Wildemann B. Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 2012, 114:331-335.
94. Kitley J., Woodhall M., Waters P., Leite M.I., Devenney E., Craig J., et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012, 79:1273-1277.
95. Rostasy K., Mader S., Schanda K., Huppke P., Gartner J., Kraus V., et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012, 69:752-756.
96. Rostasy K., Mader S., Hennes E.M., Schanda K., Gredler V., Guenther A., et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013, 19:1052-1059.
97. Sato D.K., Callegaro D., Lana-Peixoto M.A., Waters P.J., de Haidar Jorge F.M., Takahashi T., et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014, 82:474-481.
98. Kitley J., Waters P., Woodhall M., Leite M.I., Murchison A., George J., et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014, 71(3):276-283.
99. Hoftberger R., Sepulveda M., Armangue T., Blanco Y., Rostasy K., Cobo Calvo A., et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015, 21:866-874.
100. Probstel A.K., Rudolf G., Dornmair K., Collongues N., Chanson J.B., Sanderson N.S., et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation 2015, 12:46.
101. Ramanathan S., Prelog K., Barnes E.H., Tantsis E.M., Reddel S.W., Henderson A.P., et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 2015, [pii: 1352458515593406 Epub ahead of print].
102. Cobo-Calvo A., Sepulveda M., Bernard-Valnet R., Ruiz A., Brassat D., Martinez-Yelamos S., et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications. Mult Scler 2015, [pii: 1352458515591071 Epub ahead of print].
103. Chalmoukou K., Alexopoulos H., Akrivou S., Stathopoulos P., Reindl M., Dalakas M.C. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2015, 2.
104. Hacohen Y., Absoud M., Woodhall M., Cummins C., De Goede C.G., Hemingway C., et al. Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. J Neurol Neurosurg Psychiatry 2014, 85:456-461.
105. Akaishi T., Sato D.K., Nakashima I., Takeshita T., Takahashi T., Doi H., et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry 2015, [pii: jnnp-2014-310206 Epub ahead of print]. 10.1136/jnnp-2014-310206.
106. Ramanathan S., Mohammed S., Brilot F., Dale R.C. Autoimmune encephalitis: recent updates and emerging challenges. J Clin Neurosci 2014, 21(5):722-730.
107. Kleiter I., Hellwig K., Berthele A., Kumpfel T., Linker R.A., Hartung H.P., et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012, 69:239-245.
108. Min J.H., Kim B.J., Lee K.H. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012, 18:113-115.
109. Trebst C., Jarius S., Berthele A., Paul F., Schippling S., Wildemann B., et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014, 261:1-16.
110. Sakuma H., Kohyama K., Park I.K., Miyakoshi A., Tanuma N., Matsumoto Y. Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats. Brain 2004, 127:2201-2213.
111. Bettelli E., Pagany M., Weiner H.L., Linington C., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 2003, 197:1073-1081.
112. Soares R.M., Dias A.T., De Castro S.B., Alves C.C., Evangelista M.G., Da Silva L.C., et al. Optical neuritis induced by different concentrations of myelin oligodendrocyte glycoprotein presents different profiles of the inflammatory process. Autoimmunity 2013, 46:480-485.
113. Shao H., Huang Z., Sun S.L., Kaplan H.J., Sun D. Myelin/oligodendrocyte glycoprotein-specific T-cells induce severe optic neuritis in the C57BL/6 mouse. Invest Ophthalmol Vis Sci 2004, 45:4060-4065.
114. Krishnamoorthy G., Lassmann H., Wekerle H., Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 2006, 116:2385-2392.
115. Bettelli E., Baeten D., Jager A., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a devic-like disease in mice. J Clin Invest 2006, 116:2393-2402.
116. Kezuka T., Usui Y., Yamakawa N., Matsunaga Y., Matsuda R., Masuda M., et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuroophthalmol 2012, 32:107-110.
117. Tanaka M., Tanaka K. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol 2014, 270:98-99.
118. Martinez-Hernandez E., Sepulveda M., Rostasy K., Hoftberger R., Graus F., Harvey R.J., et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor alpha1 subunit in patients with isolated optic neuritis. JAMA Neurol 2015, 72:187-193.
119. Zamvil S.S., Slavin A.J. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?. Neurol Neuroimmunol Neuroinflamm 2015, 2.
120. Titulaer M.J., Hoftberger R., Iizuka T., Leypoldt F., McCracken L., Cellucci T., et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014, 75:411-428.
121. Hacohen Y., Absoud M., Hemingway C., Jacobson L., Lin J.P., Pike M., et al. NMDA receptor antibodies associated with distinct white matter syndromes. Neurol Neuroimmunol Neuroinflamm 2014, 1.
122. Mayer M.C., Breithaupt C., Reindl M., Schanda K., Rostasy K., Berger T., et al. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 2013, 191:3594-3604.
123. Spadaro M., Gerdes L.A., Mayer M.C., Ertl-Wagner B., Laurent S., Krumbholz M., et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2015, 2:295-301.
124. Kerlero de Rosbo N., Honegger P., Lassmann H., Matthieu J.M. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 1990, 55:583-587.
125. Piddlesden S.J., Lassmann H., Zimprich F., Morgan B.P., Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993, 143:555-564.
126. Saadoun S., Waters P., Owens G.P., Bennett J.L., Vincent A., Papadopoulos M.C. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2014, 2:35.
127. Jarius S., Franciotta D., Paul F., Ruprecht K., Bergamaschi R., Rommer P.S., et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010, 7:52.
128. Papadopoulos M.C., Verkman A.S. Aquaporin water channels in the nervous system. Nat Rev Neurosci 2013, 14:265-277.
129. Reindl M., Di Pauli F., Rostasy K., Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013, 9:455-461.
130. Selter R.C., Brilot F., Grummel V., Kraus V., Cepok S., Dale R.C., et al. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 2010, 74:1711-1715.
131. Ransohoff R.M., Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012, 12:623-635.
132. Louveau A., Smirnov I., Keyes T.J., Eccles J.D., Rouhani S.J., Peske J.D., et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015, 523:337-341.
133. Winger R.C., Koblinski J.E., Kanda T., Ransohoff R.M., Muller W.A. Rapid remodeling of tight junctions during paracellular diapedesis in a human model of the blood-brain barrier. J Immunol 2014, 193:2427-2437.
134. Mohammad M.G., Tsai V.W., Ruitenberg M.J., Hassanpour M., Li H., Hart P.H., et al. Immune cell trafficking from the brain maintains CNS immune tolerance. J Clin Invest 2014, 124:1228-1241.
135. Stern J.N., Yaari G., Vander Heiden J.A., Church G., Donahue W.F., Hintzen R.Q., et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med 2014, 6.
136. Reindl M., Rostasy K. MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm 2015, 2.
137. Damoiseaux J., Andrade L.E., Fritzler M.J., Shoenfeld Y. Autoantibodies 2015: from diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev 2015, 14:555-563.
138. Hayter S.M., Cook M.C. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 2012, 11:754-765.
139. Elong Ngono A., Lepetit M., Reindl M., Garcia A., Guillot F., Genty A., et al. Decreased frequency of circulating myelin oligodendrocyte glycoprotein B lymphocytes in patients with relapsing-remitting multiple sclerosis. J Immunol Res 2015, 2015:673503.
140. Hino-Fukuyo N., Haginoya K., Nakashima I., Sato D.K., Takahashi T., Misu T., et al. Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies. Brain and Development 2015, 37:849-852.